Viewing nowCombinationLinatop Duo Tablet 2.5/850 mg (Linagliptin, Metformin Hydrochloride)
Linagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.

MFDS item code 201904463 · Approved 2019.06.28 · Insurance code 657308950
Improves blood glucose control in type 2 diabetes mellitus
This medication is used to aid blood sugar control in patients with type 2 diabetes in addition to diet and exercise therapy. Linagliptin and metformin work together to effectively lower blood sugar levels. This supports patients in achieving more stable blood sugar management. With consistent use, blood sugar levels can improve, and the risk of complications can be reduced. The best effects can be expected when used alongside a healthy lifestyle. This medication improves blood sugar control in type 2 diabetes.
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the starting dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The starting dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The starting dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). 5. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The starting dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may result in a change in glycemic control; caution should therefore be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do Not Administer to the Following Patients).
This medication can cause a rare but serious side effect called lactic acidosis, and should not be used in patients with poor kidney function or conditions such as severe infections, dehydration, or acute heart disease. It should also not be administered to patients who are allergic to any of its components, or to those with type 1 diabetes, diabetic ketoacidosis, or diabetic coma. Patients with weak kidney function or the elderly should regularly monitor their kidney function while using this medication, and it is strictly prohibited in cases of severely impaired kidney function. This medication may cause hypoglycemia, so caution should be exercised for symptoms of hypoglycemia when used in combination with insulin or sulfonylureas, and the dosage of these medications may need to be adjusted if necessary. Skin conditions such as acute pancreatitis or bullous pemphigoid may occur, so if abdominal pain or blistering on the skin occurs, consult a doctor immediately. Since vitamin B12 levels may decrease with long-term use, it is recommended to check vitamin B12 status through blood tests during prolonged treatment. Women who are pregnant or may become pregnant, as well as those who are breastfeeding, are advised not to use this medication, and should consult a doctor if planning to become pregnant. This medication is not recommended for children under 10 years of age and adolescents between the ages of 10 to 17 years, as its safety and efficacy have not been established in these populations. As this medication requires careful monitoring, patients should regularly see a doctor while taking it and report any adverse reactions immediately. Additionally, this medication may interact with other medications, so it is essential to inform healthcare providers of any concurrent medications and manage them carefully.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to maintain a storage temperature between 1 to 30 degrees Celsius.
Bright orange oval film-coated tablet
60 tablets (10 tablets/PTP x 6)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.